TargetMol

Inosine pranobex

Product Code:
 
TAR-T3614
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T3614-500mg500mg£104.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T3614-1mL1 mL * 10 mM (in DMSO)£107.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Isoprinosine has a number of immunomodulatory effects, including inducing T-lymphocyte differentiation, augmenting macrophage and NK cell functions, and stimulating IL-2 production. Through these effects and others, isoprinosine shows antiviral activity and has applications against subacute sclerosing panencephalitis. It also restores depressed immune responses in Y patients after irradiation and reduces the incidence of infection in leukemia patients undergoing chemotherapy. It is most commonly used to treat the rare measles complication subacute sclerosing panencephalitis in conjunction with intrathecal interferon therapy.
CAS:
36703-88-5
Formula:
C52H78N10O17
Molecular Weight:
1115.249
Pathway:
Proteases/Proteasome; Immunology/Inflammation; Microbiology/Virology
Purity:
0.9985
SMILES:
CC(O)CN(C)C.CC(O)CN(C)C.CC(O)CN(C)C.CC(=O)Nc1ccc(cc1)C(O)=O.CC(=O)Nc1ccc(cc1)C(O)=O.CC(=O)Nc1ccc(cc1)C(O)=O.OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c1nc[nH]c2=O
Target:
IL Receptor; HIV Protease

References

Anna, et al. Cent Eur J Immunol. 2015; 40(4): 395?399. Campoli-Richards DM, et al. November 1986, Volume 32, Issue 5: 383?424. Beran J, et al. BMC Infect Dis. 2016; 16: 648.